Array Biopharma (NASDAQ: ARRY) reported Q3 EPS of $0.37, $0.38 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $6.6 million versus the consensus estimate of $6 million.

For earnings history and earnings-related data on Array Biopharma (ARRY) click here.